-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Japan's Ministry of Health, Labour and Health held a special meeting on the new crown vaccine on the 2nd, decided to free of charge for all the people to get the new crown vaccine.
is understood to be aimed at reducing the national burden at this stage, so that everyone can get vaccinated as soon as possible, as far as possible to control the emergence of serious cases and deaths.
, if there is a need to continue vaccination, the Japanese government will further adjust the relevant vaccination guidelines.
addition, the Japanese government will pay the corresponding medical expenses in accordance with the relief system provided for in the Vaccination Law in the event of impaired health after the new crown vaccine is given.
government plans to ensure the use of vaccines for all its citizens by the first half of 2021 at a cost of about 670 billion yen ($6.37 billion).
government has reached a vaccine supply agreement with several relevant pharmaceutical companies in Europe and the United States.
that since the vaccine is still in development, experts expect the vaccine to be available as soon as the end of the year.
due to the limited initial supply, the Japanese government has given priority to inoculation for medical workers treated with neo-coronary pneumonia and the elderly, who are prone to serious illness.
specific vaccination work is carried out by local governments such as municipalities and villages, and the related cost plans are borne by the central government and do not require local governments to bear the burden.
, on the other hand, some people have also voiced their reluctance to vaccinate, arguing that vaccine development time is short, clinical validation may not be sufficient, and safety cannot be effectively guaranteed.
China News Network Source: China News Network Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Metz Medical and may not be reproduced by any media, website or individual without authorization.
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
reproduce content at the same time does not represent the position of this site.
leave a message here.